1. Do you currently offer a clinical testing service for PD-L1 in non-small cell lung carcinoma (NSCLC) as off the beginning of 2017?
2. How is PD-L1 testing in NSCLC normally requested by the clinician? (please select all that apply)
3. If requested as part of a NSCLC panel of tests, how is PD-L1 testing performed in the lab
4. What sample types are processed by the lab for NSCLC testing (EGFR/ALK/PD-L1)? (please select all that apply)
5. What is the number of NSCLC samples being tested (or sent-out) are tested for:?
6. What proportion of PD-L1 NSCLC samples tested are cytology/ cytological cell block samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)
7. What proportion of PD-L1 NSCLC samples are NOT tested because the samples are EBUS/cytology samples? (per month or per year or as a percentage of PD-L1 samples tested, whichever is easier to determine)
8. What methods are used for PD-L1 testing in NSCLC and their associated clinical cut-off? (please select all that apply)
9. What is the clinical cut offs are used in relation to the antibodies selected above?
10. What IHC staining platform(s) are used in the laboratory that performs the PD-L1 testing e.g. Ventana, Dako, Leica, Menarini, Shandon, Labvision, etc? (If possible, please supply the model of the platform)
11. What percentage of samples tested have ≥1% PD-L1 expression?
12. What percentage of samples tested have ≥50% PD-L1 expression?
13. What is the average turnaround time from sample receipt to report being issued?
14. Are there bottlenecks that prevent this turnaround time from being quicker?
15. Who pays for DLBCL testing?

Download response PDL1 testing. 070417